

REPORTED July 22, 2026

CLIENT

VERIFY Peptidetestcanada.ca/verify
EMAIL Info@peptidetestcanada.ca



END CUSTOMER

NAME NextPhase Biolabs
EMAIL —
PHONE NA
ADDRESS T5A 5B4, Edmonton, Alberta, Canada

§ 01 Sample Information

FOR RESEARCH PURPOSES ONLY

Sample ID: PT-003
Compound: PT-141
Report No.: COA-2026-SC-00334
Total Mass: 68.6 mg
Appearance: Lyophilized powder

Received: 07/16/2026
Analyzed: 07/20/2026
CAS: 189691-06-3
Formula: C₅₀H₆₈N₁₄O₁₀
Mol Weight: 1025.2 g/mol

SAMPLE PHOTOGRAPH



§ 02 Analytical Results


Qualitative and Quantitative chemical analysis by Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

	SPECIFICATION	RESULT	STATUS
Compound Test:	PT-141	PT-141	PASS
Net Peptide Content:	10.00 mg	9.62 mg	
Peptide Label Accuracy:	≥ 90 %	96.2 %	
Chromatographic Purity:	≥ 98 %	99.41 %	

Chromatographic purity is the target peptide's HPLC-MS/MS principal component analysis, expressed as a percentage of total integrated peak area (Ph. Eur. 2.2.46) — it bounds peptide-related impurities only, not excipients, counter-ions, or residual water, and is separate from net peptide content. — indicates not determined.

§ 03 LC-MS/MS Detail

METHOD A · AGILENT 1290 INFINITY II + 6495 QQQ · ESI+



ROLE	TRANSITION	CE
● Quantifier	513.3 > 159.1	25 V
■ Qualifier	513.3 > 175.1	32 V

Agilent Poroshell 120 EC-C18 · 2.1×100 mm · 2.7 μm · Solvent A: 0.1 % formic acid in H₂O · Solvent B: 0.1 % formic acid in Acetonitrile

DISCLAIMER · RESEARCH USE ONLY
Results relate **only to the sample as received** and the tests performed — not to any other unit, lot, or batch. **For research use only:** not a certificate of quality, safety, efficacy, or regulatory compliance, and not for human or veterinary administration, clinical or diagnostic use, or label claims. SideChain Analytics does not manufacture, source, or sell the material and makes **no warranty, express or implied**; its liability shall not exceed the testing fee. This report may not be reproduced except in full.